Key result
Sentinel CPS is being evaluated to determine if it reduces silent brain infarcts during LAAC.
Why the study?
LAAC procedures carry risks of peri-procedural silent brain infarcts that may cause cognitive impairment, but whether mechanical neuroprotection systems during LAAC reduce this risk is unknown.
Does the Sentinel CPS reduce the number of new silent brain infarcts in patients with atrial fibrillation undergoing left atrial appendage closure?
RCT (n=240)
Double-blind
Block randomization
Yes
Does the Sentinel CPS reduce the number of new silent brain infarcts in patients with atrial fibrillation undergoing left atrial appendage closure?
This study protocol outlines a trial to evaluate whether mechanical neuroprotection during left atrial appendage closure reduces silent brain infarcts and subsequent cognitive and mood disorders.
Answers are grounded in this paper and cite their sources.
May support neuroprotection in LAA closure; leaves open confirmation of cognitive benefits in larger trials.
BACKGROUND: Left atrial appendage closure (LAAC) procedures prevent cardioembolic stroke in patients with atrial fibrillation who have contraindications to oral anticoagulant medications. However, these procedures carry certain risks of peri-procedural complications. One such complication is silent brain infarcts (SBI), which can lead to cognitive impairment and mood disturbances. The implementation of mechanical neuroprotection systems during LAAC procedures may reduce the risk of SBI and associated cognitive and mood disorders. METHODS: The LAAC-SBI trial is a prospective, multicenter, randomized, and double-blind interventional study. The study aims to enroll a total of 240 patients, with 120 patients allocated to each group. The study group will evaluate the use of the Sentinel CPS during LAAC, while the control group will undergo LAAC procedures without the Sentinel CPS. The primary endpoint of the study is the number of new SBIs or stroke foci detected by diffusion-weighted magnetic resonance imaging (DW MRI). Secondary endpoints include deterioration of cognitive function, development of dementia syndrome, and occurrence of depressive disorders. These endpoints will be assessed using questionnaire tools such as the Montreal Cognitive Assessment (MoCA), Trail Making Test (TMT), Controlled Oral Word Association Test (COWAT), and Hospital Anxiety and Depression Scale (HADS). The observational period for patients in the study is 2 years. DISCUSSION: If the study demonstrates a favorable outcome with reduced incidence of SBI and improved cognitive and mood outcomes in patients receiving cerebral protection devices during LAAC, it will have significant implications for clinical management standards. This would support the use of neuroprotection devices not only for LAAC but also in procedures such as atrial fibrillation ablation or transcatheter mitral valve interventions, where the risk of embolic events and subsequent brain injury may also be present. TRIAL REGISTRATION: ClinicalTrials.gov NCT05369195. Registration on 11.05.2022.
No takes yet. Share an insight, caveat, or question.
Streb et al. (2023) conducted an RCT in Atrial fibrillation (n=240). Sentinel Cerebral Protection System (CPS) vs. LAAC without Sentinel CPS was evaluated on Number of new silent brain infarcts (SBIs) or stroke foci detected by DW MRI. The Sentinel Cerebral Protection System will be evaluated in the LAAC-SBI randomized trial to determine if it reduces the risk of silent brain infarcts during left atrial appendage closure in 240 patients with atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: